Company intelligence / Profile preview
GeneMedicine Co., Ltd.
Hanam-si, Gyeonggi-do, South Koreagene-medicine.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
GeneMedicine has demonstrated promising preclinical data and early clinical results for its lead programs. GM101 completed a phase I trial with an excellent safety profile in triple negative breast cancer; GM103 is in a phase 1/2 basket trial targeting multiple solid tumors. The company is preparing additional candidates for clinical development. Their approach aims to overcome limitations of conventional oncolytic virotherapy through proprietary vector engineering.[3][6]
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic viruses (primarily oncolytic adenovirus)Gene therapy vectors[5][6]
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Licensing agreements with US NASDAQ-listed companies ("F" and "M", names not specified)[1]CDMO contract with WuXi AppTec[1]
Beyond the preview
Go deeper on GeneMedicine Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GeneMedicine Co., Ltd..